GURUFOCUS.COM » STOCK LIST » Industrials » Industrial Products » Mytrex Health Technologies Inc (ROCO:4431) » Definitions » Debt-to-EBITDA

Mytrex Health Technologies (ROCO:4431) Debt-to-EBITDA : -4.29 (As of Dec. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Mytrex Health Technologies Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Mytrex Health Technologies's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was NT$114 Mil. Mytrex Health Technologies's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was NT$113 Mil. Mytrex Health Technologies's annualized EBITDA for the quarter that ended in Dec. 2024 was NT$-53 Mil. Mytrex Health Technologies's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2024 was -4.29.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Mytrex Health Technologies's Debt-to-EBITDA or its related term are showing as below:

ROCO:4431' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.37   Med: 1.56   Max: 13.09
Current: 13.09

During the past 13 years, the highest Debt-to-EBITDA Ratio of Mytrex Health Technologies was 13.09. The lowest was 0.37. And the median was 1.56.

ROCO:4431's Debt-to-EBITDA is ranked worse than
93.06% of 2290 companies
in the Industrial Products industry
Industry Median: 1.72 vs ROCO:4431: 13.09

Mytrex Health Technologies Debt-to-EBITDA Historical Data

The historical data trend for Mytrex Health Technologies's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mytrex Health Technologies Debt-to-EBITDA Chart

Mytrex Health Technologies Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.37 1.47 6.65 7.09 13.09

Mytrex Health Technologies Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -137.45 5.07 11.56 2.55 -4.29

Competitive Comparison of Mytrex Health Technologies's Debt-to-EBITDA

For the Specialty Industrial Machinery subindustry, Mytrex Health Technologies's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mytrex Health Technologies's Debt-to-EBITDA Distribution in the Industrial Products Industry

For the Industrial Products industry and Industrials sector, Mytrex Health Technologies's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Mytrex Health Technologies's Debt-to-EBITDA falls into.


;
;

Mytrex Health Technologies Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Mytrex Health Technologies's Debt-to-EBITDA for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(113.551 + 112.912) / 17.297
=13.09

Mytrex Health Technologies's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(113.551 + 112.912) / -52.85
=-4.29

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Dec. 2024) EBITDA data.


Mytrex Health Technologies  (ROCO:4431) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Mytrex Health Technologies Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Mytrex Health Technologies's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Mytrex Health Technologies Business Description

Traded in Other Exchanges
N/A
Address
No. 545, Section 2, Hezhen North Road, Zhongli District, Taoyuan, TWN, 32060
Mytrex Health Technologies Inc is a Taiwan-based company engaged in the manufacturing of non-woven materials and special medical supplies. It is engaged in the development and production of melt-blown products for the protection of the environment and human health. The company offers products ranging from medical to industrial filtration materials such as various types of filtration media, lab coats or outfits, cabin filtration, vacuum cleaner filter bags, and special medical supplies. Its product categories include meltdown, mammoth bedding, and specialized medical supplies like balloon catheters and coronary stents.

Mytrex Health Technologies Headlines

No Headlines